Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 7/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 2/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885754 | 0.84 | POLB (0.41) | GRM5L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3878476 | 0.83 | RBP4 (0.43) | RBP4KDM5AGRM5MAP3K12UBE2M | |
| SCHEMBL3878875 | 0.83 | SMN1; SMN2 (0.39) | KDM5AGRM5L3MBTL3L3MBTL1CYP2D6 | |
| SCHEMBL3880543 | 0.82 | MGLL (0.35) | GRM5L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3878900 | 0.82 | HRH3 (0.37) | GRM5L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3882318 | 0.82 | SLC9A1 (0.41) | GRM5L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3879769 | 0.82 | L3MBTL1 (0.45) | RBP4L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3881503 | 0.81 | L3MBTL3 (0.37) | GRM5L3MBTL3L3MBTL1CYP2D6HRH3 | |
| SCHEMBL3877921 | 0.81 | GRM5 (0.46) | KDM5AGRM5L3MBTL3L3MBTL1CYP2D6 | |
| SCHEMBL3878461 | 0.81 | RBP4 (0.44) | RBP4GRM5L3MBTL3L3MBTL1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | RBP4 3396/4885KDM5A 2860/4885GRM5 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.